SKiN Centre for Dermatology

Running trials

• Not yet recruiting

  A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis

  NCT07914231· Phase 2· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

  NCT06220604· Phase 3· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

  NCT06095102· Phase 3· Source

• Active, not recruiting

  A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

  NCT03661866· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Psoriasis2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Source

• Completed

  A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

  NCT07006792· Phase 4· Source

• Completed

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Phase 3· Source

• Completed

  A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05633355· Phase 3· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Source